RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Glucagon—like insulin ... protein SEC22B and how it works within a liver cell to affect glucagon action. More information: ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

MBX Biosciences Inc. (NASDAQ:MBX) revealed results from its Phase 1 single ascending dose and multiple ascending dose trial ...

GLP-1 receptor agonists (GLP-1RAs) mimic the action of endogenous GLP-1 and have been shown to provide substantial benefits in the management of type 2 diabetes and obesity. Their potential role ...

The only exceptions are Survodutide, Retatrutide, and Efinopegdutide, which all have less Glucagon content than Pemvidutide. By combining direct and indirect mechanisms of action (MOA) in one drug ...

Insulin resistance refers to impaired insulin signaling and action at the level of the cell ... type 2 diabetic patients also have elevated levels of glucagon, which worsens hyperglycemia by ...

Retatrutide, a synthetic peptide with unique properties, has recently gained attention for its multifunctional roles and the ...